James F Casella
Overview
Explore the profile of James F Casella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
3627
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wonkam A, Esoh K, Levine R, Ngo Bitoungui V, Mnika K, Nimmagadda N, et al.
Nat Commun
. 2025 Mar;
16(1):2092.
PMID: 40025045
Known fetal haemoglobin (HbF)-modulating loci explain 10-24% variation of HbF level in Africans with Sickle Cell Disease (SCD), compared to 50% among Europeans. Here, we report fourteen candidate loci from...
2.
Goldenberg N, Schulman S, Kittelson J, Abshire T, Casella J, Dale R, et al.
J Thromb Haemost
. 2024 Oct;
23(2):651-656.
PMID: 39461724
Background: The Multicenter Evaluation of the Duration of Therapy for Thrombosis in Children multinational, randomized clinical trial revealed noninferiority of a 6-week vs 3-month duration of anticoagulation for the treatment...
3.
Casella J, Furstenau D, Adams R, Brambilla D, Lebensburger J, Fehr J, et al.
Am J Hematol
. 2024 Jul;
99(10):1906-1916.
PMID: 38953438
Central nervous system (CNS) injury is common in sickle cell disease (SCD) and occurs early in life. Hydroxyurea is safe and efficacious for treatment of SCD, but high-quality evidence from...
4.
Yelton S, Williams M, Young M, Fields J, Pearl M, Casella J, et al.
J Pediatr Intensive Care
. 2023 Aug;
12(3):159-166.
PMID: 37565017
Pediatric patients with moyamoya arteriopathy are at high risk for developing new onset transient or permanent neurologic deficits secondary to cerebral hypoperfusion, particularly in the perioperative period. It is therefore...
5.
Aguwa C, Cannon A, Casella J, Shapiro B, Lance E
Br J Haematol
. 2022 Dec;
200(3):377-380.
PMID: 36454537
Despite recent developmental screening guidelines, rates of neurodevelopmental disorders (NDDs) remain lower than expected in children with sickle cell disease (SCD). A retrospective chart review identified 276 eligible patients; 214...
6.
Jawed A, Papakyrikos C, Stewart R, Villagran K, Zwirlein C, Zaim N, et al.
J Addict Dis
. 2022 Aug;
41(4):341-349.
PMID: 35946477
Hospitalization can be a critical time to stabilize chronically ill patients across levels that transcend medical and social determinants of health. The use of the biopsychosocial model can be instrumental...
7.
Lance E, Cannon A, Casella J, Shapiro B
Pediatr Blood Cancer
. 2022 Jun;
69(9):e29861.
PMID: 35716349
No abstract available.
8.
Lin Z, McIntyre T, Jiang D, Cannon A, Liu P, Tekes A, et al.
Front Physiol
. 2022 Feb;
13:814979.
PMID: 35222083
Sickle cell disease (SCD) is an inherited hemoglobinopathy with an increased risk of neurological complications. Due to anemia and other factors related to the underlying hemoglobinopathy, cerebral blood flow (CBF)...
9.
Goldenberg N, Kittelson J, Abshire T, Bonaca M, Casella J, Dale R, et al.
JAMA
. 2022 Jan;
327(2):129-137.
PMID: 35015038
Importance: Among patients younger than 21 years of age, the optimal duration of anticoagulant therapy for venous thromboembolism is unknown. Objective: To test the hypothesis that a 6-week duration of...
10.
Lin Z, Lance E, McIntyre T, Li Y, Liu P, Lim C, et al.
J Magn Reson Imaging
. 2021 Oct;
55(5):1551-1558.
PMID: 34676938
Background: Blood-brain barrier (BBB) disruption may lead to endothelium dysfunction and inflammation in sickle cell disease (SCD). However, abnormalities of BBB in SCD, especially in pediatric patients for whom contrast...